ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

RPEP-035912018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Published In:
The Journal of clinical endocrinology and metabolism, 103(8), 2949-2957 (2018)
Database ID:
RPEP-03591

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-03591·https://rethinkpeptides.com/research/RPEP-03591

APA

Bone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-Yi; Fitzpatrick, Lorraine A; Mitlak, Bruce; Papapoulos, Socrates; Rizzoli, René; Dore, Robin K; Bilezikian, John P; Saag, Kenneth G. (2018). ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.. The Journal of clinical endocrinology and metabolism, 103(8), 2949-2957. https://doi.org/10.1210/jc.2018-00163

MLA

Bone, Henry G, et al. "ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.." The Journal of clinical endocrinology and metabolism, 2018. https://doi.org/10.1210/jc.2018-00163

RethinkPeptides

RethinkPeptides Research Database. "ACTIVExtend: 24 Months of Alendronate After 18 Months of Aba..." RPEP-03591. Retrieved from https://rethinkpeptides.com/research/bone-2018-activextend-24-months-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.